Coronavirus: EMA to submit Merck's anti-Covid drug to an ongoing review
Eva Deschamps / October 26, 2021
The European Medicines Agency EMA will submit the anti-Covid drug from U.S. pharmaceutical companies Merck and Ridgeback Bio to a continuing review, it announced Monday.
If the pill, called molnupiravir, gets the green light, it would be the first oral coronavirus drug to be approved.
The rolling review process allows the EMA to evaluate safety and efficacy data as they come in. Therefore, there is no need to wait for a formal application from the producer. The objective is to speed up the evaluation of an application if it is actually submitted.
The two companies themselves announced the results of the Phase 3 study earlier this month. The study appears to show that the treatment reduced the risk of hospitalization or death in the event of infection by half.
Related Posts
Coronavirus: Russian Sputnik V vaccine developers claim longer efficacy
Sylvie Claire / November 25, 2021
The developers of Sputnik V said Wednesday that the Russian vaccine was more effe...
Read More
First in Europe: Austria makes vaccination against Covid-19 mandatory
Sylvie Claire / November 20, 2021
Austria will confine its entire population as of Monday and has decided to make...
Read More
Coronavirus: Washington to lift indoor mask requirement
Eva Deschamps / November 17, 2021
The U.S. capital, one of the strictest jurisdictions for Covid-19-related measures...
Read More